IFNGR1 and neoplasm: Nonetheless, when a mixture of wild-type (WT) and IFNγR-mutant tumor cells was implanted in vivo to mimic the tumor heterogeneity often seen in patients, anti-PD-L1 therapy selected for outgrowth of the IFNγR2-mutant tumor cell clones.